传统血液透析对阿皮克萨班血度的影响
Tim Poel1, Nikki de Rouw2, Nathalie C V Péquériaux3
1Department of Nephrology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
概括
血液透析稍微降低了患者的阿皮克萨班水平,但度仍然是治疗性的. 抗Xa活性与阿皮克萨班水平相关,这表明在接受阿皮克萨班的血液透析患者中不需要调整剂量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
背景情况:
- 阿皮克萨班是一种直接的XA因子抑制剂.
- 患有功能衰竭的患者通常需要血液透析.
- 在血液透析患者中管理抗凝血是复杂的.
研究的目的:
- 为了评估血液透析对阿皮克萨班血度的影响.
- 为了确定阿皮克萨班剂量是否需要在血液透析患者中进行调整.
主要方法:
- 对接受阿皮克萨班 (2.5毫克每天两次) 和血液透析的患者的观察性研究.
- 血液样本采集在透析前,透析后2小时和透析后.
- 测量了阿皮克萨班度和抗Xa活性.
主要成果:
- 在血液透析后,阿皮克萨班度显著下降 (141.03 ng/mL至102.71 ng/mL,p=0.003).
- 艾皮克萨班水平和抗Xa活性都保持在治疗范围内.
- 在阿皮克萨班度和抗Xa活性之间观察到强烈的相关性 (r=0.935,p=0.000).
结论:
- 血液透析可以降低阿皮克萨班的血度,但不能降低到治疗水平以下的水平.
- 抗Xa活性可以作为apixaban水平的可靠替代标记物.
- 目前的阿皮克萨班剂量对于血液透析患者来说似乎是安全有效的,可能会否定同时需要低分子量肝素的需要.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
Hemodialysis I: Introduction
36
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
36
Hemodialysis II: Procedure and Complications
26
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
26
Time Course of Drug Effect
2.1K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.1K
Hepatic Drug Clearance: Effect of Protein Binding
213
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
213


